LJAC
PACB icon

L.J. Altfest & Co’s Pacific Biosciences PACB Stock Holding History

L.J. Altfest & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-47,902
Closed -$165K – 241
2020
Q2 		$165K Buy
+47,902
New +$163K 0.05% 209

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

L.J. Altfest & Co's PACB Position: Q3 2020 in Review

L.J. Altfest & Co sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 47,902 shares — an estimated $165K sold.

L.J. Altfest & Co first reported a position in PACB in Q2 2020 and held it in 1 quarter. The position peaked at $165K in Q2 2020. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

  • L.J. Altfest & Co reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
  • L.J. Altfest & Co sold 47,902 Pacific Biosciences shares in Q3 2020, an estimated $165K.
  • L.J. Altfest & Co first reported a position in Pacific Biosciences in Q2 2020 and held it in 1 quarter.
  • L.J. Altfest & Co's Pacific Biosciences position peaked at $165K in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on L.J. Altfest & Co's 13F filing for Q3 2020, filed 29 Oct 2020.